In triple-negative breast cancer, cisplatin activated MEG3/NLRP3/CASP-1 pathway to induce cell pyroptosis, which suggested that MEG3 was involved in the pyroptosis pathway of cisplatin therapy [23]. Here, MEG3 is linked to triple-negative breast carcinoma.